Caleco Pharma amends IP filing with EPO

Caleco Pharma is a healthcare company with biopharmaceutical and consumer health product development programs that develop products derived from natural sources such as plant extracts.

In response to the EU Patent Office’s Examination Report, Caleco reports that the company’s European Patent Application number 08725530.3 is amended with regard to compositions comprising derivatives and derivative combinations of Lamiridosin and Iridoid for treatment of Hepatitis C.

Caleco Pharma said the molecular specifications required in these amendments resulted in the exclusion of certain derivative claims.

However, these claims will not be abandoned, but instead, will be pursued through one or more divisional applications.

Caleco CEO John Boschert said they plan to continue to pursue a broader pipeline of semi-synthetic derivatives that will be prepared for further testing in 2011.